pcos and hyperandrogenism
PCOS is a diagnosis of exclusion requiring ≥2 of 3 updated Rotterdam criteria in adults: ovulatory dysfunction (irregular cycles), clinical or biochemical hyperandrogenism, and polycystic ovarian morphology (PCOM) on ultrasound or elevated serum AMH (2023 update — adults only; if both irregular cycles and hyperandrogenism are present, neither US nor AMH is needed). Always exclude pregnancy, thyroid disease, hyperprolactinaemia, and non-classical CAH (17-OHP) — and investigate urgently for an androgen-secreting tumour if virilisation is rapid or severe. First-line therapy is lifestyle + combined OCP (add spironolactone for refractory hirsutism; letrozole first-line for anovulatory infertility).
- Androgen-secreting ovarian or adrenal tumour: rapid-onset (<1 y) or postmenopausal severe hirsutism, virilisation (clitoromegaly, voice deepening, male-pattern balding, ↑ muscle bulk), or markedly elevated testosterone (>5 nmol/L) / DHEA-S → image adrenals and pelvis urgently to exclude adrenocortical carcinoma or ovarian tumour (do not assume PCOS).
- Teratogenicity of anti-androgens: spironolactone (and finasteride/cyproterone) can feminise a male foetus — never prescribe as monotherapy in sexually active premenopausal patients without reliable contraception.
- Endometrial hyperplasia / cancer: prolonged unopposed oestrogen in oligo/amenorrhoeic PCOS requires cycle regulation (COCP, progestin-only contraception, or periodic withdrawal bleeds).
diagnostic workup — PCOS and secondary amenorrhoea
step 1 — exclude pregnancy and mimics
In any patient presenting with secondary amenorrhoea (>3 mo if previously regular, >6 mo if irregular) or oligomenorrhoea/hyperandrogenism, test:
- Urine/serum β-hCG (always first)
- TSH (hypothyroidism or hyperthyroidism)
- Serum prolactin (hyperprolactinaemia)
- FSH, LH, and oestradiol:
- High FSH + low oestradiol (<40 y) → primary ovarian insufficiency (POI) (see menopause and hormone therapy)
- Low LH/FSH + low oestradiol → functional hypothalamic amenorrhoea (low energy availability, intensive exercise, eating disorder, stress) or pituitary disease
- Early-morning (follicular) 17-hydroxyprogesterone (17-OHP): screens for non-classical congenital adrenal hyperplasia (NCCAH) (21-hydroxylase deficiency; basal >6 nmol/L warrants cosyntropin-stimulated 17-OHP)
- Total testosterone (and calculated free T / SHBG if total T normal despite clinical signs) + DHEA-S (adrenal source); screen for cushing syndrome or acromegaly only if clinical features are present
step 2 — PCOS diagnostic criteria (2023 international guideline)
After excluding mimics, adults require ≥2 of 3:
- Irregular menstrual cycles / ovulatory dysfunction: cycles <21 or >35 days, or <8 cycles/year (>3 y post-menarche to perimenopause); or >90 days for any single cycle
- Clinical and/or biochemical hyperandrogenism: terminal-hair hirsutism (modified Ferriman–Gallwey score; ethnicity-dependent) alone predicts biochemical hyperandrogenism in adults; biochemical confirmation with total/free testosterone if signs are mild/absent
- Polycystic ovarian morphology (PCOM) OR serum AMH (adults only):
- Transvaginal US: ≥20 follicles (2–9 mm) per ovary (or ovarian volume ≥10 mL if transabdominal/older transducer)
- 2023 update: serum AMH can substitute for ultrasound to define PCOM in adults (never as a single standalone test, and never in adolescents — adolescents require both irregular cycles and hyperandrogenism; avoid US/AMH within 8 y of menarche)
- Skip US and AMH when both irregular cycles and hyperandrogenism are already present
metabolic, cardiovascular, and psychological screening (PCOS 2023)
PCOS carries lifelong cardiometabolic and mental-health risks independent of BMI:
- Glycaemic screening: 75-g OGTT is the most accurate test to detect IGT/type 2 diabetes (fasting glucose or HbA1c if OGTT not feasible); repeat every 1–3 years. Perform OGTT preconception (or early first-trimester screening — OGTT per PCOS 2023, or early HbA1c/fasting glucose per diabetes in pregnancy) and again at 24–28 weeks’ gestation
- Cardiovascular risk: regular BP, fasting lipid profile, weight/BMI (assess with sensitivity to weight stigma), and screen for obstructive sleep apnoea (increased prevalence independent of BMI)
- Mental health: screen routinely for anxiety, depression, and eating disorders regardless of body weight
management of PCOS and hirsutism (PCOS 2023)
| goal | first-line | second-line / adjuncts |
|---|---|---|
| cycle regulation & endometrial protection | combined oral contraceptive pill (COCP) (lowest effective ethinyl oestradiol 20–30 µg; no single progestin superior) | progestin-only pill / levonorgestrel IUS (endometrial protection); metformin if COCP contraindicated/declined |
| hirsutism & acne | COCP + cosmetic/mechanical laser or light hair removal (allow ≥6 months to assess hair response) | add spironolactone 25–100 mg/day (with reliable contraception) if inadequate response after 6 mo; avoid cyproterone ≥10 mg (meningioma/VTE risk; 35 µg EE + cyproterone is second-line COCP) |
| metabolic / insulin resistance | lifestyle modification (diet + exercise; weight-inclusive or weight-centric per patient goals) | metformin (especially BMI ≥25; titrate by 500 mg q1–2 wk to 1000–2500 mg/d; XR improves GI tolerance; superior to inositol) ± anti-obesity pharmacotherapy (glp-1 receptor agonists) or bariatric surgery |
| anovulatory infertility | letrozole (aromatase inhibitor — superior ovulation, clinical pregnancy, and live birth rates vs clomiphene; 2023 strong rec) | clomiphene citrate (± metformin), gonadotropins, laparoscopic ovarian drilling, or IVF (GnRH antagonist protocol + agonist trigger to prevent OHSS) |
- Pregnancy notes: metformin is not routinely recommended during pregnancy in PCOS; anti-obesity agents should not be used for fertility/pregnancy outside research settings (stop GLP-1 RAs before conception)
- Primary amenorrhoea (no menses by age 15, or >3 y post-thelarche): pelvic ultrasound to confirm uterus/Müllerian structures + β-hCG, FSH, LH, TSH, prolactin, testosterone, and karyotype (45,X Turner syndrome if high FSH + uterus present; 46,XY androgen insensitivity if uterus absent + male-range testosterone)
Prepared 2026-11-19. Not yet verified — check every number against the sources.